590 kr
Research-grade peptide material supplied as lyophilized powder. Produced under controlled conditions and supported by batch-specific analytical documentation.
For Research Use Only. Not for human or veterinary use.
590 kr
Research-grade peptide material supplied as lyophilized powder. Produced under controlled conditions and supported by batch-specific analytical documentation.
For Research Use Only. Not for human or veterinary use.
Retatrutide is a synthetic triple hormone receptor agonist peptide supplied for laboratory research use only.
Published scientific literature has investigated Retatrutide in relation to GIP, GLP-1 and glucagon receptor biology, endocrine signaling and metabolic research models.
Each batch is linked to a batch-specific Certificate of Analysis (COA).
Available documentation may include purity testing, identity verification, and batch-related analytical data.
Coskun T, Urva S, Roell WC, Qu H, Loghin C, Moyers JS, et al.
LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept.
Cell Metabolism. 2022;34(9):1234–1247.e9.
PMID: 35985340
DOI: 10.1016/j.cmet.2022.07.013
Urva S, Coskun T, Loh MT, Du Y, Thomas MK, Gurbuz S, Haupt A, et al.
LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial.
The Lancet. 2022;400(10366):1869–1881.
PMID: 36354040
DOI: 10.1016/S0140-6736(22)02033-5
Jastreboff AM, Kaplan LM, Frías JP, Wu Q, Du Y, Gurbuz S, Coskun T, et al.
Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial.
New England Journal of Medicine. 2023;389(6):514–526.
PMID: 37366315
DOI: 10.1056/NEJMoa2301972
Rosenstock J, Frias JP, Jastreboff AM, Du Y, Lou J, Gurbuz S, et al.
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA.
The Lancet. 2023;402(10401):529–544.
PMID: 37385280
DOI: 10.1016/S0140-6736(23)01053-X
Research Profile
This product is supplied strictly for laboratory research purposes.
It is not intended for human use, veterinary use, diagnostic applications, or therapeutic and clinical applications.
True Peptides does not provide dosing guidance, administration instructions, or usage recommendations.
Product Name: 10-Amino-1MQ 50 mg
LOT Number: 240710A
Expiration Date: July 18, 2028
Storage Conditions: 2–8 °C, unless otherwise specified
Use Category: Research Use Only
This batch is linked to analytical documentation intended to support traceability and laboratory recordkeeping.
The COA may include:
• batch identification
• analytical purity results
• identity verification
• method reference information
This page applies only to the lot number listed above.
Documentation shown here is batch-specific and should not be used as a reference for other lots or product versions.
This material is supplied strictly for laboratory research purposes.
It is not intended for:
• human use
• veterinary use
• diagnostic applications
• therapeutic or clinical applications
True Peptides does not provide dosing guidance, administration instructions, or usage recommendations.
All analytical data provided is batch-specific and linked to the corresponding product.
Transparency in documentation allows for:
True Peptides prioritizes accessible and verifiable documentation as a core part of its quality framework.
Peptide materials are supplied as lyophilized powders.
Recommended storage: 2–8°C refrigerated, unless otherwise specified.
Proper storage conditions are required to maintain material integrity. Stability may vary depending on peptide structure and environmental exposure.
Handling should be performed within controlled laboratory conditions.
